Dr. Weickert will present Pacylex at the OBIO® Investment Summit and Early Technology Showcase February 5-7, 2025, at the Arcadian Court & Loft, Toronto Mr. Kamdar will present Pacylex at the PWMC ...

Data from the Phase 3 PALOMA-3 study showed non-inferiority to intravenous administration meeting both co-primary pharmacokinetic (PK) endpoints, as well as a five-fold reduction in infusion-related ...

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous ...

Epidermal growth factor receptor (EGFR) is a major driver of cancer dissemination and target for anti-cancer therapies but ...

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and toxicity management in patients with EGFR-mutated non–small cell lung ...

Hope is not passive wishing but an active, dynamic process. According to Hope Theory, hope involves two components: agency and pathways. Agency is the belief in one’s capability to act ...

The company is currently developing HT-001 with intentions of submitting a new drug application via the 505(b)(2) regulatory pathway, according to the company website.

This discrepancy indicates that the etching procedure introduced extraneous conductive pathways unrelated to the VHE, thereby explaining why a reduced band gap had been observed in prior ...

Hear Daniel, husband of a lung cancer survivor, discuss the importance of comprehensive biomarker testing. EGFR-positive lung cancer patient, Ashley, shares what she would tell a newly diagnosed ...

It shows how adjusting eGFR results for body surface may improve decision results. The National Kidney Foundation published a consensus document that advocates transition to race-free eGFR ...

Excitingly, we’ve shown that targeting [the heat shock response pathway] can slow the growth of prostate cancer tumours – even for tumours that are resistant to hormone therapy.” NXP800 targets the ...